High‐affinity SEB variants are assessed for their ligand binding affinities, and immune‐stimulatory activities, and subsequently incorporated into the design of a tumor‐targeted ICE herein termed Superantigen‐based Tri‐functional Yeast‐display‐enhanced Multivalent Immune cell Engager (STYMIE). This evidence concerns the gene SETBP1 and neoplasm.